A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma

Trial Profile

A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 12 Dec 2017 Results of long term follow up of the study, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 Results published in the Adaptimmune Therapeutics Media Release
    • 11 Dec 2017 According to an Adaptimmune media release, the updated data (n=25) were presented at the annual ASH meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top